We estimated the putative causal effects of SGLT2 inhibition and genetically predicted HbA1c on the risks of prostate cancer and its subtypes using MR (Tables S2, S3, and S4; Figure S1). The gene discussed is SLC5A2; the disease is Familial prostate cancer.